BIORA THERAPEUTICS INC - BIOR STOCK NEWS

Biora Therapeutics reported their Q1 2024 financial results and provided a corporate update. They have completed dosing all patients in the clinical trial for BT-600, with results expected in late Q2 2024. Interim results showed consistent drug delivery to the colon. They will present NaviCap™ platform data at the DDW conference on May 19. Partnering progress for the BioJet oral delivery platform is ongoing. Financially, Biora raised $31 million in new capital and reported a net loss of $4.2 million for Q1 2024, an improvement from a $17.4 million net loss in Q1 2023.

Biora Therapeutics, Inc. (Nasdaq: BIOR) will report financial results and provide a corporate update for Q1 2024 on May 15, 2024. The company focuses on therapeutic delivery and will host a webcast and conference call after the market close. Investors can access the call online for 60 days.

Biora Therapeutics, Inc. (Nasdaq: BIOR) will present clinical data on the device function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024. The presentation will include results of human device function studies in healthy volunteers and patients with UC. The abstract will be presented by Shaoying Nikki Lee, PhD, Director of Clinical and Translational Science at Biora Therapeutics, Inc.

Biora Therapeutics, Inc. (Nasdaq: BIOR) announces the completion of dosing for multiple-ascending dose cohorts in the clinical trial of BT-600 for potential treatment of ulcerative colitis. Final results expected in late Q2 2024. The trial evaluated daily doses of BT-600 for seven days at 5 mg and 10 mg tofacitinib or placebo in healthy adult participants. Positive interim results from the single-ascending dose portion have been previously shared.

Biora Therapeutics, Inc. announces the issuance of a new patent related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics. The patent covers key parameters for liquid jet delivery of drugs to the gastrointestinal tract, showing promising results in preclinical testing. Biora holds a strong patent position with multiple issued patents and pending applications, positioning them as a leader in innovative therapeutic delivery technologies.

Biora Therapeutics, Inc. shares positive interim results from the phase 1 clinical trial of BT-600, a drug-device combination for ulcerative colitis treatment. The trial demonstrates successful pharmacokinetic endpoints, localized drug delivery to the colon, reduced systemic drug exposure, and improved colonic tissue exposure. The NaviCap platform shows potential for enhanced efficacy and reduced toxicity risks. The MAD portion of the trial is ongoing, with final results expected in late Q2 2024.

Biora Therapeutics, Inc. (BIOR) successfully closed a registered direct offering of 5,454,548 shares of common stock at $1.10 per share, along with a private placement of warrants. The total gross proceeds amounted to approximately $6,000,000. H.C. Wainwright & Co. served as the exclusive placement agent. The net proceeds will be utilized for operational support, ongoing clinical trials, further development of oral biotherapeutics platforms, and general corporate purposes.

Biora Therapeutics, Inc. (BIOR) announces a registered direct offering of 5,454,548 shares of common stock at $1.10 per share and a concurrent private placement of unregistered warrants. The offering is priced at-the-market under Nasdaq rules.

Biora Therapeutics, Inc. (BIOR) reports successful results from the single-ascending dose (SAD) portion of the BT-600 clinical trial, demonstrating targeted drug delivery to the colon with lower systemic drug levels. The company is progressing well with the remainder of the trial and BioJet platform. Financially, Biora reduced net debt by 75% in 2023 and raised $19.8 million through note exchanges. The company aims to conclude the BT-600 trial in Q2 2024 and plans a clinical study for ulcerative colitis patients in H2 2024.